Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | MMP2 | P08253 | 2/20 | 0.66 |
| ▸ | MMP9 | P14780 | 2/20 | 0.66 |
| ▸ | MMP12 | P39900 | 2/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.49 |
| ▸ | MMP14 | P50281 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4438683 | 0.90 | CYP2C9 (0.69) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL6933325 | 0.90 | CYP2C9 (0.74) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL8228112 | 0.90 | MMP2 (0.76) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL4734978 | 0.88 | CYP2C9 (0.72) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL8229735 | 0.88 | CYP2C9 (0.72) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL27971821 | 0.88 | CYP2C9 (0.72) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL10049356 | 0.88 | CYP2C9 (0.72) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL3640100 | 0.88 | CYP2C9 (0.72) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL8230531 | 0.85 | CYP2C9 (0.68) | HPGDCYP2C9CYP2C19MMP2MMP9 | |
| SCHEMBL8363035 | 0.85 | MMP2 (0.71) | HPGDCYP2C9CYP2C19MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4511729-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1985-04-16 | — | — | US | claimed |
| US-4502998-A | Nucleophilic substitution process | ETHYL CORPORATION (US) | 1985-03-05 | — | — | US | claimed |
| US-20100311734-A1 | Spiro Compounds Useful as Antagonists of the H1 Receptor | GLAXO GROUP LIMITED | 2010-12-09 | — | — | US | disclosed |
| US-20100311734-A1 | Spiro Compounds Useful as Antagonists of the H1 Receptor | GLAXO GROUP LIMITED | 2010-12-09 | — | — | US | disclosed |
| US-20100311734-A1 | Spiro Compounds Useful as Antagonists of the H1 Receptor | GLAXO GROUP LIMITED | 2010-12-09 | — | — | US | disclosed |
| WO-2009016085-A1 | SPIRO COMPOUNDS USEFUL AS ANTAGONISTS OF THE H1 RECEPTOR | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | WO | disclosed |
| WO-2007001335-A2 | RAMOPLANIN DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | VICURON PHARMACEUTICALS INC. (US) | 2006-09-21 | — | — | US | disclosed |
| EP-0910563-B1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2003-05-02 | — | — | EP | disclosed |
| US-6008213-A | A INHIBITOR OF VITRONECTIN RECEPTOR AND FIBRINOGEN RECEPTOR; USEFUL FOR INHIBITING PLATELET AGGREGATION AND OSTEOPOROSIS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-12-28 | — | — | US | disclosed |
| EP-0910563-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-28 | — | — | EP | disclosed |
| EP-0910563-A4 | — | — | 1999-04-28 | — | — | EP | disclosed |
| WO-1997001540-A1 | INTEGRIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-01-16 | — | — | WO | disclosed |
| US-4157399-A | Benzo(B)thiophenes | PARCOR (FR) | 1979-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211603-A1 | Ramoplanin derivatives possessing antibacterial activity | CLSPN, LMAN2, RPN2 | HPGD 1825/4885CYP2C9 4299/4885CYP2C19 4445/4885 |
| US-20100311734-A1 | Spiro Compounds Useful as Antagonists of the H1 Receptor | HCRTR1, HCRTR2, HRH3 | HPGD 570/4885CYP2C9 1359/4885CYP2C19 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.